Efficacy of Target Therapy With Crizotinib in a Patient With Alk-Positive Advanced Gastric Cancer

Siberian Journal of Oncology - Russian Federation
doi 10.21294/1814-4861-2020-19-1-141-146
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Tomsk Cancer Research Institute

Related search

Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient

Molecular and Clinical Oncology
Cancer ResearchOncology
2018English

Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

PLoS ONE
Multidisciplinary
2014English

Dramatic Response to Crizotinib in an ALK-Positive Adenocarcinoma Patient With Disseminated Intravascular Coagulation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient With IHC-Positive and FISH-Negative ALK

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Outcomes of ALK Positive Lung Cancer Patients Treated With Crizotinib or Second-Generation ALK Inhibitor: A Monoinstitutional Experience

Oncotarget
Oncology
2018English

P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience From Turkey

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A Case Report of an EML4-ALK-positive Elderly Non-Small Cell Lung Cancer Patient With a Poor PS Successfully Treated With Crizotinib

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2013English

P2.01-109 Treatment Duration—A More Reasonable Definition to Evaluate the Efficacy of Crizotinib in ALK Positive Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Efficacy of Paclitaxel and S-1 in a Patient With Advanced Pseudomyxoma Peritonei Concomitant With Gastric Cancer

General Medicine: Open Access
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy